S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
Log in

NASDAQ:IART - Integra Lifesciences Stock Price, Forecast & News

$61.96
+0.70 (+1.14 %)
(As of 12/12/2019 04:00 PM ET)
Today's Range
$60.96
Now: $61.96
$62.11
50-Day Range
$55.73
MA: $59.34
$62.27
52-Week Range
$42.14
Now: $61.96
$65.09
Volume251,302 shs
Average Volume436,280 shs
Market Capitalization$5.32 billion
P/E Ratio25.60
Dividend YieldN/A
Beta1.11
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IART
CUSIP45798520
Phone609-275-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.47 billion
Cash Flow$3.83 per share
Book Value$16.15 per share

Profitability

Net Income$60.80 million

Miscellaneous

Employees4,500
Market Cap$5.32 billion
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.


Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions

What is Integra Lifesciences' stock symbol?

Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."

When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?

Shares of Integra Lifesciences split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were distributed to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.

How were Integra Lifesciences' earnings last quarter?

Integra Lifesciences Holdings Corp (NASDAQ:IART) released its quarterly earnings results on Thursday, October, 24th. The life sciences company reported $0.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.65 by $0.03. The life sciences company had revenue of $379.10 million for the quarter, compared to analyst estimates of $376.85 million. Integra Lifesciences had a net margin of 3.99% and a return on equity of 16.83%. The firm's revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.59 earnings per share. View Integra Lifesciences' Earnings History.

When is Integra Lifesciences' next earnings date?

Integra Lifesciences is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Integra Lifesciences.

What guidance has Integra Lifesciences issued on next quarter's earnings?

Integra Lifesciences issued an update on its FY19 earnings guidance on Thursday, October, 24th. The company provided earnings per share guidance of $2.70-2.75 for the period, compared to the Thomson Reuters consensus estimate of $2.73. The company issued revenue guidance of $1.517-1.522 billion, compared to the consensus revenue estimate of $1.52 billion.

What price target have analysts set for IART?

9 equities research analysts have issued 1-year price objectives for Integra Lifesciences' stock. Their forecasts range from $50.00 to $75.00. On average, they expect Integra Lifesciences' share price to reach $61.89 in the next year. This suggests that the stock has a possible downside of 0.1%. View Analyst Price Targets for Integra Lifesciences.

What is the consensus analysts' recommendation for Integra Lifesciences?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Integra Lifesciences.

What are Wall Street analysts saying about Integra Lifesciences stock?

Here are some recent quotes from research analysts about Integra Lifesciences stock:
  • 1. According to Zacks Investment Research, "Integra LifeSciences exited the second quarter of 2019 on a strong note with better-than-expected results. Organic revenue growth was encouraging and was above the company’s expectation. Within global neurosurgery business, sales in dural access and repair increased in low-single digits on an organic basis with growth in both graft and sealant product lines. Benefiting from product launches and an enhanced sales force performance, the company envisions faster organic growth during the second half of 2019. On the flip side, escalating costs and expenses have been a major headwind for Integra Lifesciences. A tough competitive landscape adds to the woes.  Overall, Integra LifeSciences outperformed its industry in the past three months." (9/2/2019)
  • 2. Cantor Fitzgerald analysts commented, "We maintain our Neutral rating and 12-month price target of $50 on IART. Although we view IART’s long-range plan as impressive, we believe execution over the next few quarters is critical to restoring investor confidence in the stock. We think it is appropriate to stay on the sidelines at this time, but we might become more positive on the stock if the company were to execute on its integration and salesforce restructuring goals. We think IART is fairly valued at current levels, appropriately balancing the long-term opportunities with the risk of near-term disruption from the Codman acquisition and the changes to the OTT sales channel structure." (2/21/2019)

Has Integra Lifesciences been receiving favorable news coverage?

Media stories about IART stock have been trending extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Integra Lifesciences earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave media headlines about the life sciences company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the stock's share price in the next several days. View News Stories for Integra Lifesciences.

Are investors shorting Integra Lifesciences?

Integra Lifesciences saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 1,250,000 shares, an increase of 14.7% from the November 14th total of 1,090,000 shares. Based on an average daily volume of 366,100 shares, the days-to-cover ratio is currently 3.4 days. Approximately 1.8% of the shares of the stock are short sold. View Integra Lifesciences' Current Options Chain.

Who are some of Integra Lifesciences' key competitors?

What other stocks do shareholders of Integra Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra Lifesciences investors own include Intel (INTC), Celgene (CELG), Adobe (ADBE), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), NVIDIA (NVDA), Square (SQ), Activision Blizzard (ATVI), Micron Technology (MU) and Align Technology (ALGN).

Who are Integra Lifesciences' key executives?

Integra Lifesciences' management team includes the folowing people:
  • Mr. Peter J. Arduini, Pres, CEO & Director (Age 54)
  • Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 76)
  • Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 51)
  • Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 56)
  • Mr. Robert T. Davis Jr., Corp. VP and Pres of Orthopedics & Tissue Technologies (Age 60)

Who are Integra Lifesciences' major shareholders?

Integra Lifesciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (2.14%), Vaughan Nelson Investment Management L.P. (1.00%), Point72 Asset Management L.P. (0.92%), Fisher Asset Management LLC (0.85%), Tributary Capital Management LLC (0.57%) and Eagle Asset Management Inc. (0.25%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, John Mooradian, Joseph Vinhais, Keith Bradley, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy, Rhonda Germany Ballintyn, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences.

Which major investors are selling Integra Lifesciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, First Trust Advisors LP, Barclays PLC, Fisher Asset Management LLC, SG Americas Securities LLC, Squarepoint Ops LLC, Tributary Capital Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Eric Schwartz, Glenn Coleman, John Mooradian, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy and Richard E Caruso. View Insider Buying and Selling for Integra Lifesciences.

Which major investors are buying Integra Lifesciences stock?

IART stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Castleark Management LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, CWM LLC, State of Tennessee Treasury Department, Endurant Capital Management LP and Meritage Portfolio Management. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Rhonda Germany Ballintyn. View Insider Buying and Selling for Integra Lifesciences.

How do I buy shares of Integra Lifesciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Integra Lifesciences' stock price today?

One share of IART stock can currently be purchased for approximately $61.96.

How big of a company is Integra Lifesciences?

Integra Lifesciences has a market capitalization of $5.32 billion and generates $1.47 billion in revenue each year. The life sciences company earns $60.80 million in net income (profit) each year or $2.42 on an earnings per share basis. Integra Lifesciences employs 4,500 workers across the globe.View Additional Information About Integra Lifesciences.

What is Integra Lifesciences' official website?

The official website for Integra Lifesciences is http://www.integralife.com/.

How can I contact Integra Lifesciences?

Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]


MarketBeat Community Rating for Integra Lifesciences (NASDAQ IART)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  388 (Vote Outperform)
Underperform Votes:  465 (Vote Underperform)
Total Votes:  853
MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel